Literature DB >> 3957235

Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.

T Yamamoto, T Suou, C Hirayama.   

Abstract

Of 143 patients with pulmonary tuberculosis receiving isoniazid therapy, 52 (36%) had a transient elevation in serum aminotransferases. Among 74 patients taking isoniazid, rifampicin and streptomycin, 35 (47%) had such an increase, while of 69 patients taking isoniazid, amino-salicylic acid and streptomycin, 17 (24%) did; this difference was significant. Isoniazid therapy could be continued in all patients with the abnormal test results. In 36 of the patients receiving isoniazid, rifampicin and streptomycin, isoniazid and its metabolites were studied in the serum and urine using high-performance liquid chromatography after the oral administration of 10 mg per kg of isoniazid. We had chosen for this test 18 patients with normal aminotransferase levels and 18 with abnormal levels. There were 14 rapid acetylators in the patients with abnormal aminotransferase levels and 7 rapid acetylators in the patients with normal levels; this difference was significant. These results indicate that liver dysfunction is more often caused by an isoniazid/rifampicin regimen, and patients who are rapid acetylators are more susceptible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3957235     DOI: 10.1002/hep.1840060223

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Role of CYP3A in isoniazid metabolism in vivo.

Authors:  Ke Liu; Feng Li; Jie Lu; Zhiwei Gao; Curtis D Klaassen; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2013-10-29       Impact factor: 3.614

2.  CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Authors:  Nicolas Vuilleumier; Michel F Rossier; Alberto Chiappe; Florence Degoumois; Pierre Dayer; Bernadette Mermillod; Laurent Nicod; Jules Desmeules; Denis Hochstrasser
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

Review 3.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 4.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

Review 5.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

6.  Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity.

Authors:  S Fuselli; R H Gilman; S J Chanock; S L Bonatto; G De Stefano; C A Evans; D Labuda; D Luiselli; F M Salzano; G Soto; G Vallejo; A Sajantila; D Pettener; E Tarazona-Santos
Journal:  Pharmacogenomics J       Date:  2006-07-18       Impact factor: 3.550

7.  NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

Authors:  Norihide Higuchi; Naoko Tahara; Katsunori Yanagihara; Kiyoyasu Fukushima; Naofumi Suyama; Yuichi Inoue; Yoshitsugu Miyazaki; Tsutomu Kobayashi; Kohichiro Yoshiura; Norio Niikawa; Chun-Yang Wen; Hajime Isomoto; Saburou Shikuwa; Katsuhisa Omagari; Yohei Mizuta; Shigeru Kohno; Kazuhiro Tsukamoto
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

8.  Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Authors:  Getnet Yimer; Nobuhisa Ueda; Abiy Habtewold; Wondwossen Amogne; Akira Suda; Klaus-Dieter Riedel; Jürgen Burhenne; Getachew Aderaye; Lars Lindquist; Eyasu Makonnen; Eleni Aklillu
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

Review 9.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

10.  The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Authors:  Yang Xiang; Long Ma; Weidong Wu; Wei Liu; Yongguang Li; Xia Zhu; Qian Wang; Jinfeng Ma; Mingqin Cao; Qian Wang; Xuemei Yao; Lei Yang; Atikaimu Wubuli; Corinne Merle; Paul Milligan; Ying Mao; Jiayi Gu; Xiumei Xin
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.